CHILDHOOD MDS TREATED WITH AML REGIMENS

被引：0
|
作者：
HASLE, H
KERNDRUP, G
机构：
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 1995年 / 40卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [21] MLL amplification in MDS/AML
    Sambani, C.
    La Starza, R.
    Stavropoulou, C.
    Georgakakos, V.
    Manola, K.
    Rigana, H.
    Mecucci, C.
    CHROMOSOME RESEARCH, 2005, 13 : 194 - 194
  • [22] Inherited predisposition to MDS/AML
    Machin, Ana Rio
    Tawana, Kiran
    Fitzgibbon, Jude
    HEMASPHERE, 2018, 2 : 12 - 14
  • [23] Epigenetic Therapies in MDS and AML
    Griffiths, Elizabeth A.
    Gore, Steven D.
    EPIGENETIC ALTERATIONS IN ONCOGENESIS, 2013, 754 : 253 - 283
  • [24] CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY
    Steensma, D.
    Abedi, M.
    Bejar, R.
    Cogle, C.
    Foucar, K.
    Garcia-Manero, G.
    George, T.
    Grinblatt, D.
    Komrokji, R.
    Maciejewski, J.
    Pollyea, D.
    Roboz, G.
    Savona, M.
    Scott, B.
    Sekeres, M.
    Thompson, M.
    Sugrue, M.
    Swern, A.
    Nifenecker, M.
    Erba, H.
    LEUKEMIA RESEARCH, 2015, 39 : S124 - S124
  • [25] MDS、MDS/AML及AML基因突变的频谱分析
    胡偏
    毛敏
    王燕
    潘歆
    农卫霞
    龙珍珠玛
    章大谦
    张红霞
    吴广胜
    广州医药, 2018, 49 (04) : 1 - 6
  • [26] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    BLOOD, 2015, 126 (23)
  • [27] Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML
    Scott, B
    Deeg, HJ
    Storer, B
    Chauncey, T
    Petersdorf, S
    Slattery, J
    Appelbaum, FR
    LEUKEMIA & LYMPHOMA, 2004, 45 (12) : 2409 - 2417
  • [28] Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    S M Luger
    O Ringdén
    M-J Zhang
    W S Pérez
    M R Bishop
    M Bornhauser
    C N Bredeson
    M S Cairo
    E A Copelan
    R P Gale
    S A Giralt
    Z Gulbas
    V Gupta
    G A Hale
    H M Lazarus
    V A Lewis
    M C Lill
    P L McCarthy
    D J Weisdorf
    M A Pulsipher
    Bone Marrow Transplantation, 2012, 47 : 203 - 211
  • [29] Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    Luger, S. M.
    Ringden, O.
    Zhang, M-J
    Perez, W. S.
    Bishop, M. R.
    Bornhauser, M.
    Bredeson, C. N.
    Cairo, M. S.
    Copelan, E. A.
    Gale, R. P.
    Giralt, S. A.
    Gulbas, Z.
    Gupta, V.
    Hale, G. A.
    Lazarus, H. M.
    Lewis, V. A.
    Lill, M. C.
    McCarthy, P. L.
    Weisdorf, D. J.
    Pulsipher, M. A.
    BONE MARROW TRANSPLANTATION, 2012, 47 (02) : 203 - 211
  • [30] Clonal evolution in high-risk MDS and secondary AML treated with venetoclax and azacitidine
    Koch, R.
    Ganster, C.
    Dierks, S.
    Shirneshan, K.
    Rittscher, K.
    Nothnick, G.
    Becker, S.
    Shumilov, E.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 199 - 199
12345